RCS - Diaceutics PLC - Significant upgrade to Diaceutics' DXRX platform

DiaceuticsAnnouncement

21/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU6750Ha&default-theme=true

RNS Number : 6750H  Diaceutics PLC  21 March 2024

Reach

Diaceutics launches significant upgrade to its DXRX platform

New functionality will involve a best in class combination of generative AI
and integrated data solutions to improve patient outcomes

Belfast and London, 21 March 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, has
launched a significant upgrade to its DXRX platform, including industry and
technologically leading de-identification, generative AI (Diaceutics Large Lab
Model, DLLM) and new comprehensive US data sets that include data on social
determinants of health. Not only does the upgrade increase the power and
efficiency of the platform, but also the applicability of Diaceutics'
subscription services into new parts of the precision medicine lifecycle,
expanding the Company's addressable market.

This new functionality enables the DXRX platform to breakdown siloed datasets
and provide greater depth and breadth of Diaceutics' longitudinal insight of
the patient journey, at increased speed and scale. As a result of the upgrade,
multiple stakeholders within the life sciences industry can now access a best
in class, real world data set that is HIPAA compliant, at a pace that
previously would not have been possible, helping to address healthcare
inequalities and enable more patients to access appropriate therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "Our Practise Gaps
Study identified that a staggering 64.4% of patients do not get the right
treatment. We seek to address that through the insights we provide, and
today's platform upgrade will empower healthcare providers to make timely and
accurate treatment decisions, ultimately benefiting more patients."

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Jordan Clark, Chief Data Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKKBKOBKDCNB